MG Saemaeul Geumgo Launches 'All-in-One Cancer Mutual Aid' with Enhanced Coverage for High-Cost Cancer Treatments

Saemaeul Geumgo announced on the 23rd that it has launched the "MG All-in-One Cancer Mutual Aid" to help ease the financial burden of treatment costs following a cancer diagnosis.

This new product is characterized by its expanded coverage across the entire spectrum of cancer treatment and by rationally adjusting its subscription criteria. It provides coverage for cancer surgery, radiation therapy, and anticancer drug therapy once per year, for up to 10 years after a cancer diagnosis.

Reflecting advances in medical technology, it has strengthened coverage for high-cost, specialized treatments such as da Vinci robotic surgery, particle beam radiation therapy, and CAR-T anticancer drug therapy. In addition, it applies a coverage system that takes into account the entire treatment process, including inpatient and outpatient care, rehabilitation, and precision tests. Some high-cost treatment coverages, which were previously offered only as five-year renewable policies, can now be selected as non-renewable options, reducing the burden of long-term premium increases.

The subscription requirements have also been relaxed. Applicants with diabetes can join if they meet certain conditions under separate criteria, while members with hypertension or hyperlipidemia are subject to the same requirements as regular members. The product is designed to enhance accessibility for Saemaeul Geumgo members and to help ease their premium burden.

A Saemaeul Geumgo representative stated, "We have designed the product to alleviate the long-term treatment costs that occur during cancer treatment and to enable a wide range of members to join under reasonable conditions. We will continue to develop products that consider members' medical expenses and coverage gaps in the future."

This content was produced with the assistance of AI translation services.